BAG3 DCM Gene Therapy Clinical Trial Studies Webinar Recording 4 15 26

The Genetic Cardiomyopathy Awareness Consortium hosted this webinar: Overview of Gene Therapy Clinical Trial Studies for BAG3-DCM During this educational webinar Rocket Pharmaceuticals provided high-level overviews of clinical trials and adeno-associated virus (AAV) gene therapy for BAG3 cardiomyopathy. Dr. Mayur Kasetty and Dr. Barry Greenberg also presented more detailed information on RP-A701 BAG3 Gene Therapy.  The RP-A701 BAG3 Gene Therapy is an investigational gene therapy being developed specifically for people with dilated cardiomyopathy caused by a BAG3 mutation. The investigational therapy is designed to deliver a working copy of the BAG3 gene to heart muscle cells, with the goal of helping those cells produce the BAG3 protein at more typical levels. By addressing the underlying genetic cause of the disease, this investigational approach is intended to support healthier heart cell function and slow or stabilize disease progression. A Question & Answer Session was held at the end. Presenters: Mayur Kasetty, MD Associate Vice President, AAV Global Program Head Rocket Pharmaceuticals Barry Greenberg, MD, FHFSA UC San Diego Health, Cardiology Distinguished Professor of Medicine Director of Advanced Heart Failure Treatment Program